Twenty-one. That’s the total number of people on Earth who currently have a Neuralink implant, according to the company’s own January 2026 count. Not two hundred, not two thousand, just twenty-one, spread across the US, Canada, and the UK, every one of them under a clinical trial protocol that pays for their own surgery. It’s an oddly small number for a technology that shows up in headlines like it’s already reshaping how millions of people live.
That gap between hype and headcount is the real story of neurotech in 2026, and it isn’t a story about whether the technology works. Early results are genuinely striking: patients typing 40 words a minute by thought alone, composing emails, playing video games, regaining independence they’d been told was permanently gone. The harder question is who gets to be one of those patients, and what happens once these devices leave the trial and become products with real price tags. Because right now, almost every dollar figure attached to neurotech points toward exactly the kind of stratified access this field claims it wants to avoid.
Who’s actually getting a brain implant right now
No brain-computer interface has a retail price you can look up today, because in 2026, exactly zero of them are for sale. Every human with an implanted BCI is a research participant, and that distinction matters more than the marketing suggests it should.
Take stock of where the leading players actually stand. Neuralink has implanted 21 people as of late January 2026, per the company’s own participant count. Synchron, backed by Jeff Bezos and Bill Gates, holds a Breakthrough Device designation and an investigational device exemption, not a commercial approval. Its confirmatory trial for the Stentrode implant is set to enroll patients across multiple US sites through 2026, and only a successful outcome there would let the company file for the first-ever premarket approval of a permanently implanted BCI, per reporting on the trial. Precision Neuroscience is a step ahead in one narrow sense: its 1,024-electrode Layer 7 array won FDA 510(k) clearance in 2025, but only for temporary use during surgery, up to 30 days, not as a permanent home for someone’s daily communication.
None of that is commercially available yet. All of it is currently free to enrolled patients, because trial sponsors cover the procedure. 🧠 That’s the part casual coverage tends to skip: right now, the only “price” of entry is qualifying for a study, which is its own quiet form of gatekeeping, built on diagnosis, location, and which hospital happens to run a trial near you.
Neuralink: 21 implants worldwide, PRIME study, quadriplegia or ALS required
Synchron: Stentrode, IDE plus Breakthrough designation, confirmatory trial enrolling through 2026
Precision Neuroscience: Layer 7, FDA-cleared for 30-day surgical use only, not a long-term implant
Non-invasive EEG wearables: already commercial, roughly $200 to $800, no FDA device review required for wellness claims
So what happens once a trial ends and the free ride stops? That’s where this gets uncomfortable.
The price tag problem: from LASIK math to six-figure reality
Elon Musk has compared a future Neuralink implant’s cost to LASIK eye surgery, something like $2,000 to $3,000 for the hardware once production scales up. It’s a satisfying number to say out loud. It’s also, according to Sacra’s breakdown of the company’s economics, nowhere close to where things sit today: roughly $10,000 for hardware alone, and closer to $40,000 once surgery and support are folded in. Estimates that account for insurance markups push the figure toward $50,000, and some industry analysts expect the first true commercial BCI to land closer to $50,000 to $100,000, in line with what deep brain stimulation and cochlear implants already cost patients.
That’s assuming insurance covers it at all, which mostly it doesn’t yet. A Health Affairs Forefront analysis lays the problem out plainly: Medicare coverage decisions are diagnosis-based, and implantable BCIs don’t fit neatly into categories built for one specific cause of paralysis. The authors argue for coverage tied to what a patient can functionally do, not which diagnosis code they carry, because the current system locks people out on a technicality that has nothing to do with medical need. The Centers for Medicare and Medicaid Services rolled out a new RAPID pathway in April 2026 to sync FDA approval timing with Medicare coverage decisions, but as STAT News reported, it stops short of guaranteeing automatic reimbursement.
Even trial participation has an expiration date. A Government Accountability Office report on BCI policy found that some participants have had implants removed simply because study funding ran out, with no ongoing medical support arranged after the fact. Picture learning to speak again through a device, then having it switched off because a grant cycle closed. That’s not a hypothetical for a handful of people. It has already happened.
Hardware plus surgery, current estimate: $10,000 to $50,000 per Neuralink-style implant
Deep brain stimulation, an approved analog: $35,000 to $100,000
Cochlear implants, another approved analog: $30,000 to $50,000
Musk’s long-term target: $2,000 to $3,000, widely described as aspirational rather than current
Which of these numbers ends up on an actual hospital bill by 2030 will decide a lot about who gets to participate. What’s your bet: the optimistic $2,000, or the six-figure reality most analysts expect? 👇
Three different neurotechs, three different inequality problems
This is where it pays to get picky about language, because “neurotech” isn’t one product with one access problem. It’s at least three separate categories, and treating them as a single story is how bad takes get made.
Medical BCIs, the Neuralink and Synchron kind, exist to restore lost function for people with paralysis, ALS, or stroke. The equity question there is blunt, even if the answer is hard: does insurance cover it, and does a hospital near you even perform the procedure? Consumer neurotech is a different animal entirely. Devices like the Neurosity Crown and Muse headsets, covered in our own device roundup, sell for a few hundred dollars and track focus or relaxation rather than restoring anything at all. They’re unregulated wellness gadgets, not medical devices, and the access question there is closer to “can you afford a nice pair of headphones” than “can you afford brain surgery.”
Then there’s military neurotech, and it’s the one nobody brings up at dinner. DARPA’s N3 program has spent years funding non-surgical, bidirectional interfaces built for able-bodied soldiers, not patients, aimed at letting a warfighter control drones or absorb battlefield data faster than any keyboard allows. That’s a national-level inequality problem, not an individual one. Whichever government funds the deepest research program gets the strategic edge, and taxpayers, not patients, are footing that bill.
Medical BCIs: restore lost function, insurance-gated, regulated as medical devices
Consumer EEG wearables: track cognitive states, unregulated, priced like electronics
Military neurotech: government-funded, aimed at strategic advantage, no individual purchase involved
If you’re building in this space, the funding model, the regulator, and the buyer are completely different for each category. Treating them as one market with one inequality story gets the diagnosis wrong before you’ve even written the prescription. Which of the three worries you more: the paralyzed patient priced out of a working implant, or the wealthy non-patient buying a cognitive edge nobody medically needs? We’d genuinely like to know, drop it in the comments.
The global gap nobody’s actively closing
Zoom out from the United States and the picture gets starker. A 2026 IntechOpen analysis of neurotechnology in the Global South found that only 2.7 percent of neurotech journal publications between 2010 and 2021 came out of Latin America, a region that holds roughly 8 percent of the world’s population. The researchers describe the resulting gap as a “technological abyss,” and it isn’t a subtle one: patents, advanced hardware, and R&D funding concentrate almost entirely in the United States, Europe, and China.
There’s a genuinely hopeful counter-trend here, and it doesn’t get the press that Neuralink does. Open-source hardware projects like OpenBCI have pushed the cost of a research-grade EEG rig down from tens of thousands of dollars to somewhere in the $500 to $1,500 range, low enough that university labs in Colombia, India, and elsewhere are now publishing original BCI research on the same boards a hobbyist could order online. It won’t get anyone a Stentrode implant, but it has meaningfully lowered the floor for who gets to do neurotech research at all, rather than just read about it from the outside. 🌍
Latin America: 2.7% of neurotech publications, 2010 to 2021, despite a far higher population share
Global concentration: R&D, patents, and manufacturing sit mostly in the US, EU, and China
Counter-trend: open-source EEG hardware now costs $500 to $1,500, down from lab-grade prices in the tens of thousands
Result: more Global South labs publishing original BCI research, even without implant-level technology of their own
Lowering the cost of entry-level tools doesn’t close the gap at the high end, where the actual therapeutic implants live. But it does mean the next generation of researchers building those implants might not all come from the same five zip codes.
Can policy get ahead of the market for once
NeurotechMag readers should be watching Chile closely right now, because it’s the most interesting natural experiment in the field. In 2021, Chile became the first country to amend its constitution to protect neurorights, explicitly including a citizen’s right to non-discriminatory access to neurotechnology, not just protection of their brain data. In 2023, the country’s Supreme Court used that framework to order Emotiv, a US consumer-neurotech company, to delete a former senator’s brain data entirely.
The follow-up legislation, bill 13,828-19, is still working its way through Chile’s Chamber of Deputies as of April 2026, and a Stanford Law School analysis points out that even this pioneering framework leaves gray areas around inferred mental data. Still, Chile has done something the United States hasn’t attempted: it wrote equitable access into the same legal document that protects mental privacy, rather than treating access as a separate problem for CMS to sort out later. Mexico and Brazil are reportedly drafting similar frameworks of their own.
The US approach, by contrast, is still fighting the access battle one coverage decision at a time, device by device, diagnosis by diagnosis. Neither model has actually solved the problem yet. Only one of them has decided that access is a right worth writing down before the market finishes deciding it for everyone else.
So here’s the question hanging over the whole field: will BCI pricing follow the smartphone’s path, where a device that once cost thousands became a $200 commodity within a decade, or will it follow the private jet’s path, a tool that stays permanently out of reach for everyone but a narrow slice of patients and buyers? The engineering side of that answer is mostly settled. The policy side is still being written, in Santiago, in Washington, and in every legislature deciding whether “neurorights” means anything beyond a nice phrase in a constitution.